Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Correlation of VDR and FOXP3 immunohistochemical expression and clinical data in classic Hodgkin lymphomaClinical FeaturesVDR and FOXP3 DiffuseN(%)VDR and FOXP3 Focal/AbsentN(%)VDR Diffuse and FOXP3 Focal/AbsentN(%)VDR focal/absent and FOXP3 diffuseN(%)TotalN(%)P Value aAge (years) > 452 (22.2)7 (77.8)009 (100)0.3 ≤ 457 (35)10 (50)03 (15)20 (100)Gender Male4 (19)15 (71.4)02 (9.5)21 (100)0.02* Female5 (62.5)2 (25)01 (12.5)8 (100)B Symptoms Present6 (35.2)9 (52.9)02 (11.7)17 (100)> 0.9 Absent2 (25)5 (62.5)01 (12.5)8 (100)Unknown1 (25)3 (75)004 (100)Ann Arbor Stage I/IIA4 (50)4 (50)008 (100)0.4 IIB/III/IV5 (27.7)10 (55.5)03 (16.6)18 (100)Unknown03 (100)003 (100)IPS Score 0 to 23 (37.5)3 (37.5)02 (25)8 (100)0.3 3 to 72 (18.1)8 (72.7)01 (9)11 (100)Unknown01 (100)001 (100)Extranodal involvement YES3 (21.4)10 (71.4)01 (7.1)14 (100)0.2 NO6 (46.1)5 (38.5)02 (15.4)13 (100)Unknown02 (100)002 (100)Histopathology NS7 (36.8)9 (47.4)03 (15.8)19 (100)0.6 MC1 (20)4 (80)005 (100) LR1 (100)0001 (100)NANOS04 (100)004 (100)NABone Marrow Involvement Yes05 (100)005 (100)0.053 No9 (45)8 (40)03 (15)20 (100)Not evaluated04 (100)004 (100)EBER Positive1 (20)4 (80)005 (100)> 0.9 Negative6 (30)12 (60)02 (10)20 (100) Not evaluated2 (50)1 (25)01 (25)4 (100)Remission after first-line treatment Yes7 (36.8)10 (52.6)02 (10.5)19 (100)> 0.9 No2 (33.3)3 (50)01 (16.7)6 (100) Unknown04 (100)004 (100)Outcome at the end of observation Alive5 (31.2)8 (50)03 (18.8)16 (100)> 0.9 Dead1 (25)3 (75)004 (100)Unknown3 (33.3)6 (66.7)009 (100)Fisher’s exact testa VDR and FOXP3 diffuse vs VDR and FOXP3 focal/absent*P value is significant (< 0.05)Abbreviations:EBER EBV-encoded small RNA, FOXP3 forkhead Box P3, LR lymphocyte rich, MC mixed cellularity, NOS not otherwise specified, NS nodular sclerosis, VDR vitamin D receptor

Source: Clinical characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Immunohistochemical expression of vitamin D receptor and forkhead box P3 in classic Hodgkin lymphoma: correlation with clinical and pathologic findings

Study design awaiting verification · BMC Cancer · 2020

Original publication title

Immunohistochemical expression of vitamin D receptor and forkhead box P3 in classic Hodgkin lymphoma: correlation with clinical and pathologic findings

Gaurav K. Gupta; Tanupriya Agrawal; Monika Pilichowska

© The Author(s) 2020

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In summary, quantity of FOXP3 positive T-cells in CHL microenvironment seems to correlate with VDR expression. Clinical stage show a trend of inverse correlation with expression of VDR and quantity of FOXP3 positive T-cells. These findings suggest that VDR could be a possible prognostic and therapeutic target in CHL.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Expression of forkhead box P3 (FOXP3), a key regulator of T-cell function, in the tumor immune microenvironment is related to survival in classic Hodgkin lymphoma (CHL). Vitamin D receptor (VDR), a transcription factor agonists have been shown to induce FOXP3 expression in T-cells and enhance recruitment of these cells to the inflammatory sites. VDR expression is CHL has been described. However, there is no data on expression of VDR in context of quantity of FOXP3 positive cells in CHL.

Source: Background

Abstract: What methods does the paper describe?

We examined and correlated immunohistochemical expression of VDR and FOXP3 along with clinical and pathology findings in 29 cases of CHL.

Source: Methods

Abstract: Results

VDR was expressed in Hodgkin Reed-Sternberg (HRS) cells and background lymphocytes and FOXP3 was expressed in background lymphocytes. 82% of CHL cases, regardless of the subtype, expressed VDR and in majority of the cases, VDR expression was directly proportional to the quantity of FOXP3 expressing lymphocytes in the tumor microenvironment. In cases with higher clinical stage (III/IV), only 28.5% of cases diffusely expressed VDR and FOXP3 compared to 71.4% showing focal positivity. Whereas in cases with lower clinical stages (I/II), the expression pattern of VDR and FOXP3 was almost similar (41.6% diffuse versus 33.3% focal).

Interestingly, focal VDR and FOXP3 expression pattern was significantly higher among males. Mixed cellularity cases showed predilection for focal VDR and FOXP3 expression (80% cases); whereas nodular sclerosis subtype had focal and diffuse VDR and FOXP3 expression patterns in similar proportion. Cases with diffuse VDR and FOXP3 expression were less likely to have bone marrow involvement. Epstein Barr virus: encoded small RNA (EBER) positive cases were predominantly focally positive (80%) for VDR and FOXP3.

Source: Results

Abstract: Conclusions

In summary, quantity of FOXP3 positive T-cells in CHL microenvironment seems to correlate with VDR expression. Clinical stage show a trend of inverse correlation with expression of VDR and quantity of FOXP3 positive T-cells. These findings suggest that VDR could be a possible prognostic and therapeutic target in CHL.

Source: Conclusions
Authors’ abstract

Background

Expression of forkhead box P3 (FOXP3), a key regulator of T-cell function, in the tumor immune microenvironment is related to survival in classic Hodgkin lymphoma (CHL). Vitamin D receptor (VDR), a transcription factor agonists have been shown to induce FOXP3 expression in T-cells and enhance recruitment of these cells to the inflammatory sites. VDR expression is CHL has been described. However, there is no data on expression of VDR in context of quantity of FOXP3 positive cells in CHL.

Methods

We examined and correlated immunohistochemical expression of VDR and FOXP3 along with clinical and pathology findings in 29 cases of CHL.

Results

VDR was expressed in Hodgkin Reed-Sternberg (HRS) cells and background lymphocytes and FOXP3 was expressed in background lymphocytes. 82% of CHL cases, regardless of the subtype, expressed VDR and in majority of the cases, VDR expression was directly proportional to the quantity of FOXP3 expressing lymphocytes in the tumor microenvironment. In cases with higher clinical stage (III/IV), only 28.5% of cases diffusely expressed VDR and FOXP3 compared to 71.4% showing focal positivity. Whereas in cases with lower clinical stages (I/II), the expression pattern of VDR and FOXP3 was almost similar (41.6% diffuse versus 33.3% focal).

Interestingly, focal VDR and FOXP3 expression pattern was significantly higher among males. Mixed cellularity cases showed predilection for focal VDR and FOXP3 expression (80% cases); whereas nodular sclerosis subtype had focal and diffuse VDR and FOXP3 expression patterns in similar proportion. Cases with diffuse VDR and FOXP3 expression were less likely to have bone marrow involvement. Epstein Barr virus: encoded small RNA (EBER) positive cases were predominantly focally positive (80%) for VDR and FOXP3.

Conclusions

In summary, quantity of FOXP3 positive T-cells in CHL microenvironment seems to correlate with VDR expression. Clinical stage show a trend of inverse correlation with expression of VDR and quantity of FOXP3 positive T-cells. These findings suggest that VDR could be a possible prognostic and therapeutic target in CHL.

Publication and source details

Original title: Immunohistochemical expression of vitamin D receptor and forkhead box P3 in classic Hodgkin lymphoma: correlation with clinical and pathologic findings

Gaurav K. Gupta; Tanupriya Agrawal; Monika Pilichowska

BMC Cancer · 2020

© The Author(s) 2020https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T16:03:07.075975+00:00

DOI: 10.1186/s12885-020-07026-6 · PMC7282135